UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with margin leverage, the analyst tells investors in a ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

In a report released on February 12, Pablo de Renteria from Kepler Capital maintained a Buy rating on Laboratorios Farmaceuticos Rovi (0ILL – Research Report), with a price target of €82.00.

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above ...

No deserto de Nevada, um complexo subterrâneo altamente protegido mantém em funcionamento parte do programa nuclear dos Estados Unidos. Conhecido como U1a, o local é usado para experimentos que ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program ...

Most outdoor brand logos are bland as a soggy sandwich left out in the rain. But not Patagonia's. Their logo is like a breath of fresh mountain air in a world of corporate stuffiness. I remember the ...

Jornalista e pós-graduada em Teoria da Comunicação. Também é radialista, com passagens por várias emissoras de rádio em São Paulo. Está na Folha desde 2018.

Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, Spin Therapeutics, pH Pharma, Novartis, Sanofi and Grifols, and research grants from GlaxoSmithKline and Grifols, outside the ...